GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » MedCap AB (OSTO:MCAP) » Definitions » Sloan Ratio %

MedCap AB (OSTO:MCAP) Sloan Ratio % : -1.20% (As of Dec. 2024)


View and export this data going back to 2004. Start your Free Trial

What is MedCap AB Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

MedCap AB's Sloan Ratio for the quarter that ended in Dec. 2024 was -1.20%.

As of Dec. 2024, MedCap AB has a Sloan Ratio of -1.20%, indicating the company is in the safe zone and there is no funny business with accruals.


MedCap AB Sloan Ratio % Historical Data

The historical data trend for MedCap AB's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MedCap AB Sloan Ratio % Chart

MedCap AB Annual Data
Trend Apr15 Apr16 Apr17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Sloan Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.14 3.85 6.17 5.81 -1.20

MedCap AB Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.80 6.69 5.31 2.04 -1.20

Competitive Comparison of MedCap AB's Sloan Ratio %

For the Medical Devices subindustry, MedCap AB's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MedCap AB's Sloan Ratio % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, MedCap AB's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where MedCap AB's Sloan Ratio % falls into.


;
;

MedCap AB Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

MedCap AB's Sloan Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Sloan Ratio=(Net Income (A: Dec. 2024 )-Cash Flow from Operations (A: Dec. 2024 )
-Cash Flow from Investing (A: Dec. 2024 ))/Total Assets (A: Dec. 2024 )
=(207.4-360
--128.8)/1991.4
=-1.20%

MedCap AB's Sloan Ratio for the quarter that ended in Dec. 2024 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Dec. 2024 )
=(207.3-360
--128.8)/1991.4
=-1.20%

MedCap AB's Net Income for the trailing twelve months (TTM) ended in Dec. 2024 was 56 (Mar. 2024 ) + 56.8 (Jun. 2024 ) + 52.9 (Sep. 2024 ) + 41.6 (Dec. 2024 ) = kr207 Mil.
MedCap AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2024 was 92.4 (Mar. 2024 ) + 70.9 (Jun. 2024 ) + 70.2 (Sep. 2024 ) + 126.5 (Dec. 2024 ) = kr360 Mil.
MedCap AB's Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2024 was -35.4 (Mar. 2024 ) + -16.1 (Jun. 2024 ) + -11.1 (Sep. 2024 ) + -66.2 (Dec. 2024 ) = kr-129 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MedCap AB  (OSTO:MCAP) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Dec. 2024, MedCap AB has a Sloan Ratio of -1.20%, indicating the company is in the safe zone and there is no funny business with accruals.


MedCap AB Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of MedCap AB's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


MedCap AB Business Description

Traded in Other Exchanges
Address
Sundbybergsvagen 1, Solna, SWE, 171 73
MedCap AB acquires and develops profitable, market-leading niche companies in the Nordic life science industry. It is diversified into two business areas namely Medical technology and Specialist medicines. Medical Technology mainly develops and sells various medical technology products and services. Its Specialist medicines develop and sell medicines within the regulatory classes of registered, extemporaneous and licensed medicines.

MedCap AB Headlines